MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Champions Oncology Inc

Ouvert

SecteurSoins de santé

6.47 0.31

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.45

Max

7.07

Chiffres clés

By Trading Economics

Revenu

702K

236K

Ventes

1M

15M

P/E

Moyenne du Secteur

42.412

89.037

Marge bénéficiaire

1.57

Employés

213

EBITDA

1.1M

612K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+71.43% upside

Dividendes

By Dow Jones

Prochains Résultats

10 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.4M

100M

Ouverture précédente

6.16

Clôture précédente

6.47

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 360 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Champions Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 janv. 2026, 23:49 UTC

Principaux Mouvements du Marché

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 janv. 2026, 21:12 UTC

Principaux Mouvements du Marché

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 janv. 2026, 21:00 UTC

Acquisitions, Fusions, Rachats

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 janv. 2026, 20:29 UTC

Principaux Mouvements du Marché

Chip Makers Gain After Trump Calls Off European Tariffs

21 janv. 2026, 20:04 UTC

Principaux Mouvements du Marché

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 janv. 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 janv. 2026, 22:39 UTC

Résultats

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 janv. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 janv. 2026, 21:35 UTC

Acquisitions, Fusions, Rachats

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 janv. 2026, 21:19 UTC

Résultats

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 janv. 2026, 20:45 UTC

Acquisitions, Fusions, Rachats

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 janv. 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 janv. 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 janv. 2026, 20:27 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 janv. 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 janv. 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 janv. 2026, 20:26 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 janv. 2026, 20:23 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 janv. 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 janv. 2026, 20:19 UTC

Acquisitions, Fusions, Rachats

Deutsche Boerse Group Agrees to Buy Allfunds

21 janv. 2026, 20:08 UTC

Résultats

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 janv. 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 janv. 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 janv. 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 janv. 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 janv. 2026, 19:24 UTC

Résultats

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 janv. 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 janv. 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparaison

Variation de prix

Champions Oncology Inc prévision

Objectif de Prix

By TipRanks

71.43% hausse

Prévisions sur 12 Mois

Moyen 12 USD  71.43%

Haut 12 USD

Bas 12 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

5.77 / 7.61Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

177 / 360Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
help-icon Live chat